Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.
about
Use of Atypical Antipsychotics in the Treatment of Autistic DisorderEfficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisAripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-AnalysisCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewCanadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorderMonitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patientsClinical utility of the risperidone formulations in the management of schizophrenia.Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation.Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionalityPsychotic disorders in children and adolescents: a primer on contemporary evaluation and managementMetabolic, digestive, and reproductive adverse events associated with antimanic treatment in children and adolescents: a retrospective cohort study.Some side effects and effcts on physical activity of second-generation antipsychotics: A study in children and adolescentsChild/Adolescent anxiety multimodal study: evaluating safety.Child and adolescent psychiatrists' reported monitoring behaviors for second-generation antipsychoticsCardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychoticsPharmacological interventions for bipolar youth: developmental considerations.Antipsychotic treatment patterns and aggressive behavior among adolescents in residential facilities.Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics.Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.Psychotropic medication monitoring checklists: use and utility for children in residential care.SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics.More than just milk: a review of prolactin's impact on the treatment of anorexia nervosa.Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.Bridging the gap from evidence to policy and practice: reducing the progression to metabolic syndrome for children and adolescents on antipsychotic medication.Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations.Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management.Cardiovascular Safety of Concomitant Use of Atypical Antipsychotics and Long-Acting Stimulants in Children and Adolescents With ADHD.Antipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System.Identification and counseling for obesity among children on psychotropic medications in ambulatory settings.Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists.Neurological adverse events associated with antipsychotic treatment in children and adolescents.Cardiovascular and neurological adverse events associated with antidepressant treatment in children and adolescents.Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children.Lagging skills contribute to challenging behaviors in children with autism spectrum disorder without intellectual disability.Practitioner Review: Definition, recognition, and treatment challenges of irritability in young people.Olanzapine Versus Risperidone in Children and Adolescents with Psychosis: A Meta-Analysis of Randomized Controlled Trials.Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review.An Innovative, Interdisciplinary Model of Care for Inpatient Child Psychiatry: an Overview.
P2860
Q22241555-11A59D5E-4184-45A7-B5E0-41612F84298BQ24606868-1C4B02C1-0200-4350-92C8-1A55B0B3FBD9Q28073540-E7E64C91-23C6-4ED9-BCA5-2E00E6BF86DEQ28079821-62C801BB-5129-413F-BCC7-4450E7CA0DD9Q28260681-0B53B9ED-5BE4-45D1-B8A5-47547F729503Q28275063-7BD065A1-44C7-4CDD-AA18-81DD39D5B8FFQ30429721-F2FC09FB-A13A-4666-8D33-92911A50D9F3Q33411020-0034F3B6-9FB2-4803-91DC-B1DE67BEB218Q33694959-378851DC-B183-4509-A23B-E4A49070F0E6Q33975802-11C0BCBD-5495-4A69-B091-28E9084C9F20Q34318121-96C68A8B-2E19-498E-ACD8-18D92FCF4CC7Q34659629-0110F9A1-8328-4AD9-9C06-EF5882FFFA25Q35185333-EFEC151C-A719-4A3B-80D3-DDB4AF76996CQ35641776-647D8B01-4A4C-4473-BF5A-5A7537CE8075Q35844289-8F6D0942-05EE-4ACB-A2BE-8AFB715EBA44Q36634438-27968B5F-F215-4058-8425-B5328DAC6B55Q36799433-3E9A5DCF-3D2B-46D4-B7B3-EA9DAE951F4DQ36946132-5047686A-2966-4269-AECD-29771A7933BDQ36965451-8C9B8F5C-BAED-4B76-A0B7-2A7D739DA8B1Q37061277-291EE4B0-35DE-4581-B6B8-DFA699DE4AF2Q37567443-4D228278-5E7D-419F-9AA5-5CC0AC370740Q37724890-4DEDADE2-7A38-4299-92CE-81B2A42654CFQ37903006-8CA45E37-2FC5-44D8-A0AE-1A1E30C3DF4CQ37947095-DC59224A-F2B8-45D0-BE7F-99F851F631FBQ38050714-965F7CFD-439A-41E9-A74C-AAA1AA1886E8Q38090490-0067B26B-301D-423C-9E20-69CC787ADF9EQ38448948-20BA5FAE-1A7A-483A-9BE3-39D982B30653Q38504254-50239C97-201E-4E7B-8564-CF1EDA286213Q40400512-73DA78D9-0975-4A58-A0B7-C2095DECE5BBQ41488659-6C921A57-D91E-4441-9DD2-E4E94B531BC4Q44223285-114A29D1-1420-4265-AD0F-C675CB9791F6Q44387572-107191AB-ED62-4D84-A1BF-F98C5AC7CAE7Q44682540-9FBFB0B8-3099-4395-9BFF-44137F34A310Q46101913-290D5B48-F3C7-4B43-B5FE-FF9DA6DF8D7DQ47161187-89962556-4A8F-4138-B47B-98FC0C94482AQ47287438-0DD75966-6C07-4025-A00E-898D2774910AQ47586182-AB6E2958-0928-4391-B97E-30C52F4B0D8CQ47642665-4D966BF0-5F13-404A-B313-371F1A139A5EQ47783378-82F6E217-7658-4F5F-9644-0EA091AB4A75Q48090742-8A7D6B47-64F1-4588-A4EE-B1ECE1F0B59C
P2860
Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Recognizing and monitoring adv ...... s in children and adolescents.
@ast
Recognizing and monitoring adv ...... s in children and adolescents.
@en
type
label
Recognizing and monitoring adv ...... s in children and adolescents.
@ast
Recognizing and monitoring adv ...... s in children and adolescents.
@en
prefLabel
Recognizing and monitoring adv ...... s in children and adolescents.
@ast
Recognizing and monitoring adv ...... s in children and adolescents.
@en
P2093
P1476
Recognizing and monitoring adv ...... s in children and adolescents.
@en
P2093
Anil K Malhotra
Christoph U Correll
Julie B Penzner
Tahir Mughal
Tariq Javed
Umesh H Parikh
P304
P356
10.1016/J.CHC.2005.08.007
P50
P577
2006-01-01T00:00:00Z